AU2010267640B2 - N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for Alzheimer's disease - Google Patents

N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for Alzheimer's disease Download PDF

Info

Publication number
AU2010267640B2
AU2010267640B2 AU2010267640A AU2010267640A AU2010267640B2 AU 2010267640 B2 AU2010267640 B2 AU 2010267640B2 AU 2010267640 A AU2010267640 A AU 2010267640A AU 2010267640 A AU2010267640 A AU 2010267640A AU 2010267640 B2 AU2010267640 B2 AU 2010267640B2
Authority
AU
Australia
Prior art keywords
antibody
terminal truncated
protofibrils
alzheimer
protofibril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010267640A
Other languages
English (en)
Other versions
AU2010267640A1 (en
Inventor
Par Gellerfors
Lars Lannfelt
Linda Soderberg
Karin Tegerstedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioarctic AB
Original Assignee
Bioarctic Neuroscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Neuroscience AB filed Critical Bioarctic Neuroscience AB
Publication of AU2010267640A1 publication Critical patent/AU2010267640A1/en
Application granted granted Critical
Publication of AU2010267640B2 publication Critical patent/AU2010267640B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2010267640A 2009-06-29 2010-06-29 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for Alzheimer's disease Active AU2010267640B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29
US61/221,105 2009-06-29
PCT/IB2010/052947 WO2011001366A1 (en) 2009-06-29 2010-06-29 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2010267640A1 AU2010267640A1 (en) 2012-01-19
AU2010267640B2 true AU2010267640B2 (en) 2015-03-05

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010267640A Active AU2010267640B2 (en) 2009-06-29 2010-06-29 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for Alzheimer's disease

Country Status (16)

Country Link
US (2) US20120100129A1 (cg-RX-API-DMAC7.html)
EP (2) EP3892633A1 (cg-RX-API-DMAC7.html)
JP (3) JP2012532094A (cg-RX-API-DMAC7.html)
AU (1) AU2010267640B2 (cg-RX-API-DMAC7.html)
CA (1) CA2765602C (cg-RX-API-DMAC7.html)
CY (1) CY1124034T1 (cg-RX-API-DMAC7.html)
DK (1) DK2448968T3 (cg-RX-API-DMAC7.html)
ES (1) ES2864049T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210611T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053949T2 (cg-RX-API-DMAC7.html)
LT (1) LT2448968T (cg-RX-API-DMAC7.html)
PL (1) PL2448968T3 (cg-RX-API-DMAC7.html)
PT (1) PT2448968T (cg-RX-API-DMAC7.html)
SI (1) SI2448968T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100237T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011001366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP2325209A3 (en) 2006-03-23 2011-08-03 BioArtic Neuroscience AB Improved protofibril selective antibodies and the use thereof
ES2661925T3 (es) 2010-02-26 2018-04-04 Bioarctic Ab Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías
AU2012228236B2 (en) * 2011-03-16 2016-10-27 Vivoryon Therapeutics N.V. Diagnostic antibody assay
JO3537B1 (ar) 2014-07-10 2020-07-05 Bioarctic Neuroscience Ab أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
SG10201912842VA (en) 2016-07-14 2020-02-27 Bioarctic Ab Brain delivery protein
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2019309938A1 (en) 2018-07-24 2021-03-11 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
EP3998280A4 (en) * 2019-07-08 2023-06-21 TERUMO Kabushiki Kaisha HYBRIDOME AND METHOD FOR PRODUCTION, MONOCLONAL ANTIBODY AND METHOD FOR PRODUCTION
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
AU2021278935A1 (en) 2020-05-26 2022-12-08 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
PH12022552829A1 (en) 2020-06-26 2023-06-14 Bioarctic Ab Alpha-synuclein protofibril-binding antibodies
JP2024525559A (ja) 2021-07-09 2024-07-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病治療用バイオマーカー
WO2023034230A1 (en) 2021-08-30 2023-03-09 Eisai R&D Mangement Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
AU2022439338A1 (en) 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
AU2023410175A1 (en) 2022-12-22 2025-07-03 Bioarctic Ab Antibody which binds to abetape3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005123775A1 (en) * 2004-06-21 2005-12-29 Bioarctic Neuroscience Ab Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
DE60016227T2 (de) * 1999-08-04 2005-12-15 Northwestern University, Evanston Globularer aufbau vom amyloid-beta- protein und deren verwendungen
EP1309341A2 (en) * 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
JP4633788B2 (ja) * 2004-04-13 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー 抗ｐ−セレクチン抗体
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
TWI355389B (en) * 2004-07-30 2012-01-01 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide a
EP2325209A3 (en) * 2006-03-23 2011-08-03 BioArtic Neuroscience AB Improved protofibril selective antibodies and the use thereof
PT2207568T (pt) * 2007-11-16 2017-09-01 Univ Rockefeller Anticorpos específicos para a forma de protofibrilha da proteína beta-amilóide
EP3470079A1 (en) * 2008-04-29 2019-04-17 BioArctic AB Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005123775A1 (en) * 2004-06-21 2005-12-29 Bioarctic Neuroscience Ab Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof

Also Published As

Publication number Publication date
DK2448968T3 (da) 2021-04-12
WO2011001366A1 (en) 2011-01-06
AU2010267640A1 (en) 2012-01-19
JP2017197531A (ja) 2017-11-02
SMT202100237T1 (it) 2021-05-07
EP2448968B1 (en) 2021-01-27
JP6884025B2 (ja) 2021-06-09
CY1124034T1 (el) 2022-05-27
ES2864049T3 (es) 2021-10-13
EP2448968A1 (en) 2012-05-09
JP2019218362A (ja) 2019-12-26
CA2765602C (en) 2021-05-25
PL2448968T3 (pl) 2021-09-13
SI2448968T1 (sl) 2021-07-30
CA2765602A1 (en) 2011-01-06
EP3892633A1 (en) 2021-10-13
US20120100129A1 (en) 2012-04-26
HRP20210611T1 (hr) 2021-05-28
PT2448968T (pt) 2021-04-30
JP2012532094A (ja) 2012-12-13
US20230295283A1 (en) 2023-09-21
HUE053949T2 (hu) 2021-08-30
LT2448968T (lt) 2021-05-10

Similar Documents

Publication Publication Date Title
US20230295283A1 (en) N-terminal truncated protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's
KR101591206B1 (ko) 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
US20200215209A1 (en) Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders
KR101600095B1 (ko) 모노클로널 항 베타 아밀로이드 항체
JP6128535B2 (ja) 抗体及びその利用
CN101325972B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体
JP2022528459A (ja) 融合構築物及びその使用
HK40057935A (en) Antibodies selective for n-terminaltruncated amyloid-p protofibrils/oligomers
HK40007334A (en) Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synucleinrelated disorders
AU2015200604B2 (en) Use of anti-amyloid beta antibody in ocular diseases
HK1124532B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)